Unknown

Dataset Information

0

Design and Evaluation of Tumor-Specific Dendrimer Epigenetic Therapeutics.


ABSTRACT: Histone deacetylase inhibitors (HDACi) are promising therapeutics for cancer. HDACi alter the epigenetic state of tumors and provide a unique approach to treat cancer. Although studies with HDACi have shown promise in some cancers, variable efficacy and off-target effects have limited their use. To overcome some of the challenges of traditional HDACi, we sought to use a tumor-specific dendrimer scaffold to deliver HDACi directly to cancer cells. Here we report the design and evaluation of tumor-specific dendrimer-HDACi conjugates. The HDACi was conjugated to the dendrimer using an ester linkage through its hydroxamic acid group, inactivating the HDACi until it is released from the dendrimer. Using a cancer cell model, we demonstrate the functionality of the tumor-specific dendrimer-HDACi conjugates. Furthermore, we demonstrate that unlike traditional HDACi, dendrimer-HDACi conjugates do not affect tumor-associated macrophages, a recently recognized mechanism through which drug resistance emerges. We anticipate that this new class of cell-specific epigenetic therapeutics will have tremendous potential in the treatment of cancer.

SUBMITTER: Zong H 

PROVIDER: S-EPMC4522184 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Design and Evaluation of Tumor-Specific Dendrimer Epigenetic Therapeutics.

Zong Hong H   Shah Dhavan D   Selwa Katherine K   Tsuchida Ryan E RE   Rattan Rahul R   Mohan Jay J   Stein Adam B AB   Otis James B JB   Goonewardena Sascha N SN  

ChemistryOpen 20150413 3


Histone deacetylase inhibitors (HDACi) are promising therapeutics for cancer. HDACi alter the epigenetic state of tumors and provide a unique approach to treat cancer. Although studies with HDACi have shown promise in some cancers, variable efficacy and off-target effects have limited their use. To overcome some of the challenges of traditional HDACi, we sought to use a tumor-specific dendrimer scaffold to deliver HDACi directly to cancer cells. Here we report the design and evaluation of tumor-  ...[more]

Similar Datasets

| S-EPMC2884961 | biostudies-literature
| S-EPMC3894720 | biostudies-other
| S-EPMC6023550 | biostudies-literature
| S-EPMC3754779 | biostudies-literature
| S-EPMC4516881 | biostudies-literature
| S-EPMC7772155 | biostudies-literature
| S-EPMC6154901 | biostudies-literature
| S-EPMC2743221 | biostudies-other
| S-EPMC5839975 | biostudies-literature
| S-EPMC6276292 | biostudies-literature